Tag Title
-
Media ReleaseNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
-
Media ReleaseNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
-
Media ReleaseNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
-
Media ReleaseNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
-
Media ReleaseNovartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
-
Media ReleaseNovartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
-
Media ReleaseNovartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
-
Story
When you think of the word ‘cancer’, what are the first words that spring to mind? -
Media ReleaseNovartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
-
Media ReleaseNovartis resumes production and delivery of radioligand therapy medicines ahead of schedule
-
Media ReleaseNew Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy